US 10,947,199 B2Granted

Spiro and cyclic bis-benzylidene proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders

AssigneeUp Therapeutics, Inc.

InventorYung-Nien Chang

Life of this patent

Estimating the term…

Abstract

Described herein are spiro and cyclic bis-benzylidine proteasome inhibitors, which inhibit the proteasome function through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used for the treatment of cancers/diabetes/neurological disorders.

Claims7

Dependent claims

A compound selected from the group consisting of:

Dependencies are inferred from the claim text.

Facts

Application: 16/481,562Filed 30 Jan 2018 · us provisional application
Priority: 30 Jan 2017
Published: US 2019/0365726 A15 Dec 2019
Granted: 16 Mar 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
C07D 221/20
Condensed with carbocyclic rings or ring systems: spiro-condensed ring systems
A61K 31/397
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having four-membered rings, e.g. azetidine
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…

Family

Application62/451,920Us provisional application · filed 30 Jan 2017
US 2019/0365726 A1Pre-grant publication · published 5 Dec 2019
US 10,947,199 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results